Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma.

Abstract

Rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) is regarded as the first-line treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL), but it is often necessary to reduce the dose or prolong the intervals between doses. In our center, dose reduction is performed with elderly patients with DLBCL… (More)
DOI: 10.3109/10428194.2013.780654

Topics

Cite this paper

@article{Aoki2013EfficacyAT, title={Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma.}, author={Kazunari Aoki and Takayuki Takahashi and Sumie Tabata and Masayuki Kurata and Akiko Matsushita and Kenichi Nagai and Takayuki Ishikawa}, journal={Leukemia & lymphoma}, year={2013}, volume={54 11}, pages={2441-7} }